NasdaqGM - Nasdaq Real Time Price ? USD Protagonist Therapeutics, Inc. (PTGX) Follow Compare 46.23 -1.38 (-2.90%) At close: 4:00 PM EST 46.23 0.00 (0.00%) After hours: 4:07 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 22 hours ago PTGX -2.90% Protagonist Therapeutics: Q3 Earnings Snapshot NEWARK, Calif. AP) — Protagonist Therapeutics Inc. PTGX) on Thursday reported a loss of $33.2 million in its third quarter. Associated Press Finance ? 23 hours ago PTGX -2.90% Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative ... ACCESSWIRE ? yesterday PTGX -2.90% Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at ... ACCESSWIRE ? 3 days ago PTGX -2.90% Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases We recently published a list of 8 High Growth High Margin Stocks to Invest In Now. In this article, we are going to take a look at where Protagonist Therapeutics Inc. (NASDAQ:PTGX) stands against other high growth high market stocks to invest in. How Market Trends Shape Opportunities When investor confidence is high, capital tends […] Insider Monkey ? 21 days ago PTGX -2.90% ^GSPC State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 1,101,218 shares of Protagonist Therapeutics Inc (NASDAQ:PTGX). This transaction increased State Street Corp's total holdings in the company to 3,183,542 shares. The shares were purchased at a price of $45 each, reflecting a strategic move by the firm to bolster its position in the biotechnology sector. GuruFocus.com ? 23 days ago PTGX -2.90% STT Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines Truist Securities initiated coverage on Protagonist Therapeutics Inc (NASDAQ:PTGX), citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity. Protagonist Therapeutics’ lead assets, rusfertide and JNJ-2113, have shown promising clinical results across various trials, leading to partnerships with Takeda Pharmaceutical Co Ltd (NYSE:TAK) and Johnson & Johnson (NYSE:JNJ). Truist models peak end user unadjusted sales of $2 Benzinga ? last month PTGX -2.90% JNJ TFC Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put... Simply Wall St. ? last month PTGX -2.90% Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and ... ACCESSWIRE ? 2 months ago PTGX -2.90% Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago PTGX -2.90% GBIO Protagonist Therapeutics: Q2 Earnings Snapshot NEWARK, Calif. AP) — Protagonist Therapeutics Inc. PTGX) on Tuesday reported a loss of $30.6 million in its second quarter. Associated Press Finance ? 3 months ago PTGX -2.90% Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint portion of the studies in Q4 2024 JNJ-2113 Phase 2b ANTHEM clinical trial in moderate-to-severe ... ACCESSWIRE ? 3 months ago PTGX -2.90% RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and ... ACCESSWIRE ? 3 months ago PTGX -2.90% Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and ... ACCESSWIRE ? 3 months ago PTGX -2.90% Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I ... ACCESSWIRE ? 3 months ago PTGX -2.90% Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one ... ACCESSWIRE ? 3 months ago PTGX -2.90% Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. Zacks ? 3 months ago PTGX -2.90% 3 Growth Stocks No One Is Watching (But They Should Be) Larger-capitalization enterprises command exceptional predictability with their businesses. They’re often storied franchises with globally recognizable brands that people consume on the regular. Investors love them because it’s usually easily to forecast how they’ll perform in the future. But when it comes to overlooked growth stocks, predictability goes out the window. Now, what goes in the window is greater potentiality. That’s the balance, the ying-yang if you will of the market. If you want InvestorPlace ? 3 months ago FLYW DHT PTGX -2.90% Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 Protagonist Therapeutics is poised to join the S&P SmallCap 600 next Wednesday, replacing copper and aluminum wire manufacturer Encore Wire. Investor's Business Daily ? 4 months ago PTGX -2.90% Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. PR Newswire ? 4 months ago PRYMF PRYMY PTGX -2.90% Performance Overview Trailing total returns as of 11/8/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return PTGX S&P 500 YTD +101.61% +25.70% 1-Year +180.69% +36.94% 3-Year +37.02% +27.63%
